Rocket Pharmaceuticals (RCKT) Profit After Tax (2014 - 2026)

Rocket Pharmaceuticals has reported Profit After Tax for 13 years, with the latest figure at -$47.6 million in Q1 2026.

• Quarterly Profit After Tax rose 22.4% year-over-year to -$47.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$209.4 million (up 18.85% YoY) and the FY2025 annual result came in at -$223.1 million, up 13.77% from the prior year.
• Profit After Tax retreated to -$47.6 million in Q1 2026 per RCKT's latest filing, from -$42.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$42.5 million in Q4 2025 and troughed at -$69.6 million in Q2 2024.
• A 5-year average of -$58.6 million and a median of -$60.3 million in 2024 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax sank 57.57% in 2022, then grew 29.49% in 2025.
• Over 5 years, Profit After Tax stood at -$66.7 million in 2022, then grew by 10.59% to -$59.7 million in 2023, then declined by 1.12% to -$60.3 million in 2024, then advanced by 29.49% to -$42.5 million in 2025, then fell by 11.89% to -$47.6 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$47.6 million, -$42.5 million, and -$50.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.